BioSpace News Archive

ImaginAb Inc. today announced that it has entered into a multi-year, non-exclusive licensing collaboration with Merck, known as MSD outside the United States and Canada.

Paperless validation will help fuel fast paced advancements in life science research, translational and consumer genomics, and molecular diagnostics

International Research Conference Draws Multi disciplinary Body of Experts to Cold Spring Harbor Laboratory

Adoption of membrane microfiltration in milk is one of the trends being witnessed in the global market

Presentations to include results from the dose escalation stage of phase 1b COSMIC-021 study of cabozantinib in combination with atezolizumab in previously untreated advanced renal cell carcinoma

Data presented from updated analysis of full innovaTV 201 expansion cohort in recurrent or metastatic cervical cancer

Picosun Group strengthens its position in the healthcare market with new PicoMEDICAL™ solutions specially developed for the needs of medical device manufacturers.

Data from abemaciclib, pemetrexed and ramucirumab late-stage clinical development programs in multiple difficult-to-treat tumor types

ImmunoGen, Inc. today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany.

Leap Therapeutics, Inc. today announced that data from the study of DKN-01 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced gastroesophageal cancer will be presented in a poster presentation at the European Society of Medical Oncology (ESMO) 2018 Annual Congress, taking place October 19-23, 2018 in Munich, Germany.